Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Human cytokeratin 5.|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||Neat|
|Immunohistochemistry (Paraffin) (IHC (P))||Neat|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-91105 detects Cytokeratin 5 + 6 from human samples.
MA1-91105 has been successfully used in immunohistochemistry (paraffin and frozen tissue) applications.
The MA1-91105 immunogen is: Human cytokeratin 5.
The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations in these genes have been associated with a complex of diseases termed epidermolysis bullosa simplex. The type II cytokeratins are clustered in a region of chromosome 12q12-q13.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma.
MA1-91105 was used in immunohistochemistry - paraffin section to characterize two cases of primary thymic adenocarcinoma with enteric differentiation
|Moser B,Schiefer AI,Janik S,Marx A,Prosch H,Pohl W,Neudert B,Scharrer A,Klepetko W,Müllauer L||The American journal of surgical pathology (39:541)||2015|
Molecular portrait-based correlation between primary canine mammary tumor and its lymph node metastasis: possible prognostic-predictive models and/or stronghold for specific treatments?
MA1-91105 was used in immunohistochemistry - paraffin section to determine the relationship between the molecular phenotype of the primary canine mammary tumors and lymph node metastasis
|Beha G,Brunetti B,Asproni P,Muscatello LV,Millanta F,Poli A,Sarli G,Benazzi C||BMC veterinary research (8:null)||2012|
Morphology of the myoepithelial cell: immunohistochemical characterization from resting to motile phase.
MA1-91105 was used in immunohistochemistry - paraffin section to assess a panel of markers for the identification of four different myoepithelial cell morphological types in normal and neoplastic mammary glands
|Beha G,Sarli G,Brunetti B,Sassi F,Ferrara D,Benazzi C||TheScientificWorldJournal (2012:null)||2012|
Antigenicity testing by immunohistochemistry after tissue oxidation.
MA1-91105 was used in immunohistochemistry - paraffin section to determine the effects of chemical oxidation, photo-oxidation, and artificial drying on the degradation of immunoreactivity of tissue samples
|Blind C,Koepenik A,Pacyna-Gengelbach M,Fernahl G,Deutschmann N,Dietel M,Krenn V,Petersen I||Journal of clinical pathology (61:79)||2008|
Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance.
MA1-91105 was used in immunohistochemistry to study the immunohistochemical expression of hyaluron synthase-2 in breast carcinoma and its association with aggressive forms of the disease
|Lien HC,Lee YH,Jeng YM,Lin CH,Lu YS,Yao YT||Histopathology (65:328)||2014|
Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC).
MA1-91105 was used in immunohistochemistry to determine the prevalence of BRCA1 germline mutations in young onset TNBC
|Andrés R,Pajares I,Balmaña J,Llort G,Ramón Y Cajal T,Chirivella I,Aguirre E,Robles L,Lastra E,Pérez-Segura P,Bosch N,Yagüe C,Lerma E,Godino J,Miramar MD,Moros M,Astier P,Saez B,Vidal MJ,Arcusa A,Ramón y Cajal S,Calvo MT,Tres A||Clinical and translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (16:280)||2014|
|Not Applicable||Not Cited||
Claudin 1 expression in basal-like breast cancer is related to patient age.
MA1-91105 was used in immunohistochemistry to discuss alterations in claudin 1 localization in basal-like breast cancer subtype
|Blanchard AA,Ma X,Dueck KJ,Penner C,Cooper SC,Mulhall D,Murphy LC,Leygue E,Myal Y||BMC cancer (13:null)||2013|
Differential expression of moesin in breast cancers and its implication in epithelial-mesenchymal transition.
MA1-91105 was used in immunohistochemistry to study the immunohistochemical expression of moesin in different types of breast cancer and its potential role in the epithelial-mesenchymal transition
|Wang CC,Liau JY,Lu YS,Chen JW,Yao YT,Lien HC||Histopathology (61:78)||2012|
Significance of TRIM29 and ß-catenin expression in non-small-cell lung cancer.
MA1-91105 was used in immunohistochemistry to study non-small cell lung cancer and the potential clinicopathological significance of TRIM29 and beta-catenin expression
|Zhou ZY,Yang GY,Zhou J,Yu MH||Journal of the Chinese Medical Association : JCMA (75:269)||2012|
Primary malignant deciduoid peritoneal mesothelioma: a report of the cytohistological and immunohistochemical appearances.
MA1-91105 was used in immunohistochemistry to investigate deciduoid features of malignant mesothelioma by histomorphological and immunohistochemical evaluation
|Ustun H,Astarci HM,Sungu N,Ozdemir A,Ekinci C||Diagnostic cytopathology (39:402)||2011|
Expression of CD44 and MMP-2: possible association with histopathological features of pleuro-pulmonary solitary fibrous tumors.
MA1-91105 was used in immunohistochemistry to investigate the relationship between the level of CD44/MMP-2 and histopathological characteristics in solitary fibrous tumors
|Dem¿ra¿ F,Cakir E,Alpar S,Ta¿tepe I,Kaya S||Turk patoloji dergisi (27:127)||2011|
Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.
MA1-91105 was used in immunohistochemistry to study the prognostic value of survivin in patients with basaloid triplet-negative breast cancer
|Dogu GG,Ozkan M,Ozturk F,Dikilitas M,Er O,Ozturk A||Medical oncology (Northwood, London, England) (27:34)||2010|
Dendritic cell sarcomas/tumours of the breast: report of two cases.
MA1-91105 was used in immunohistochemistry to report on two cases of dendritic cell sarcomas/tumours of the breast
|Kapucuoglu N,Percinel S,Ventura T,Lang R,Al-Daraji W,Eusebi V||Virchows Archiv : an international journal of pathology (454:333)||2009|
The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
MA1-91105 was used in immunohistochemistry to investigate the expression of cytokeratin 5/6 in a subset of invasive lobular carcinoma of the breast and its prognostic significance
|Fadare O,Wang SA,Hileeto D||Human pathology (39:331)||2008|
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
MA1-91105 was used in immunohistochemistry to study the prognostic features of basal-like breast tumors in a series of hormone receptor-negative invasive breast cancer tumors
|Liu H,Fan Q,Zhang Z,Li X,Yu H,Meng F||Human pathology (39:167)||2008|
Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature.
MA1-91105 was used in immunohistochemistry to report two clinical cases of biphasic malignant mesothelioma with osseous differentiation
|Demirag F,Unsal E,Tastepe I||Lung cancer (Amsterdam, Netherlands) (57:233)||2007|
An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
MA1-91105 was used in immunohistochemistry (paraffin) to study triple negative breast cancer in Chinese women.
|Zhang J,Wang Y,Yin Q,Zhang W,Zhang T,Niu Y||International journal of clinical and experimental pathology (6:1380)||2013|
Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural study.
MA1-91105 was used in immunohistochemistry to present a case of not otherwise specified-type sarcoma with CD10 expression in the left breast.
|Yang GZ,Li J,Jin H,Ding HY||Diagnostic pathology (8:null)||2013|
Selection for EGFR gene amplification in a breast epithelial cell line with basal-like phenotype and hereditary background.
MA1-91105 was used in immunocytochemistry to establish and characterize an epithelial cell line derived from a breast carcinoma from a patient with a strong family history of breast cancer but no known breast cancer susceptibility mutation
|Ingthorsson S,Halldorsson T,Sigurdsson V,Friðriksdottir AJ,Bodvarsdottir SK,Steinarsdottir M,Johannsson O,Magnusson MK,Ogmundsdottir HM,Gudjonsson T||In vitro cellular and developmental biology. Animal (47:139)||2011|
Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
MA1-91105 was used in immunohistochemistry to determine the activation profile of EGFR, PDGFRB, and PDGFRA receptors and their downstream effectors in diffuse malignant peritoneal mesothelioma specimens
|Perrone F,Jocollè G,Pennati M,Deraco M,Baratti D,Brich S,Orsenigo M,Tarantino E,De Marco C,Bertan C,Cabras A,Bertulli R,Pierotti MA,Zaffaroni N,Pilotti S||European journal of cancer (Oxford, England : 1990) (46:2837)||2010|
58 kDa cytokeratin; CK-5; CK-6A; CK-6D; cytokeratin 6A; cytokeratin 6C; cytokeratin 6D; Cytokeratin-5; Cytokeratin-6A; cytokeratin-6C; Cytokeratin-6D; cytokeratin-6E; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; K5; K6A; kamp-keratin derived antimicrobial peptide; KDAMP; keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types); keratin 5, type II; keratin 6A, , type II; keratin 6A, type II; keratin K6h; Keratin type II cytoskeletal 5; Keratin type II cytoskeletal 6A; Keratin type II cytoskeletal 6B; keratin, epidermal type II, K6A; Keratin, type II cytoskeletal 5; Keratin, type II cytoskeletal 6A; Keratin-5; Keratin-6A; keratin-6C; KRT5; KRT6A; KRT6B; KRT6D; KRTL1; type-II keratin Kb12; Type-II keratin Kb5; Type-II keratin Kb6
CK-6C; CK-6E; CK5; CK6A; CK6C; CK6D; DDD; DDD1; EBS2; K5; K6A; K6C; K6D; KRT5; KRT5A; KRT6A; KRT6C; KRT6D; PC3